AiCuris
is a Germany-based pharmaceutical company that discovers, researches and develops antiviral and antibacterial agents for the treatment of infectious diseases... Read moreAiCuris
is a Germany-based pharmaceutical company that discovers, researches and develops antiviral and antibacterial agents for the treatment of infectious diseases... Read more
News
Nov 01, 2024
Clinical Trials Arena
AiCuris: AiCuris commences Phase I trial of AIC468 for BK virus treatment
Jul 17, 2024
FinanzNachrichten
AiCuris: AiCuris Announces Milestone Achievements Further Validating its Pipeline of Anti-viral Solutions for Immunocompromised Patients
Jan 24, 2024
Yahoo
AiCuris: AiCuris and the German Center for Infection Research (DZIF) Sign Collaboration and License Option Agreement
Jan 09, 2024
FinanzNachrichten
AiCuris: AiCuris Anti-infective Cures AG: AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients
Sep 28, 2023
FinanzNachrichten
AiCuris: AiCuris Anti-infective Cures AG: AiCuris' AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients
Aug 25, 2023
Pharmabiz
AiCuris: AiCuris gets 30 million Euros milestone payment from MSD following US FDA approval of Prevymis in second indication
Jul 06, 2023
FinanzNachrichten
AiCuris: AiCuris Anti-infective Cures AG: AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients
Sep 29, 2022
FinanzNachrichten
AiCuris: AiCuris Anti-Infective Cures AG: AiCuris' Innovation Accelerator AiCubator Calls for Innovative Proposals to Propel Anti-Infective Drug Development in The Third Round
Sep 08, 2022
centralcharts
Press Release: AiCuris : DGAP-News: AiCuris nominates team of researchers from the Universittsklinikum Erlangen as one of the 2022 winners of AiCubator Resident Status, a corporate innovation accelerator initiative
Apr 08, 2022
centralcharts
Press Release: AiCuris : DGAP-News: AiCuris nominates Madam Therapeutics with its innovative peptide approach to fight AMR as the first winner of the AiCubator Resident Status in 2022
AiCuris Competitors
1
2
3
4
5
6
7
8
9
10